News

Xoma 052 demonstrated biological activity in patients with type 2 diabetes as measured by diabetes and inflammatory markers. The interim analysis of two single-dose, dose-escalation, Phase I studies

The Lead 4 study was a 26-week randomized trial that compared the efficacy and safety of two different doses of liraglutide (1.2mg and 1.8mg, QD) to placebo, all

As the executive director, Mr Abhaya will be directing the corporate administrative and business activities, building and managing the team, creating and executing the strategic vision of LifeCell

The financing consists of a significant product development loan from the Finnish Funding Agency for Technology and Innovation, Tekes, and an equity funding from Midroc New Technology, a

The primary objectives of the Phase I portion of this clinical trial are to determine the dose limiting toxicities (DLTs) and maximum tolerated dose and to assess the

Novartis has also filed marketing authorization applications for RAD001 with the European Medicines Agency (EMEA) and the Swiss Agency for Therapeutic Products (Swissmedic). The proposed brand name for

Scientists at the National Cancer Institute’s (NCI’s) Laboratory of Experimental Carcinogenesis and the surgery branch of the NCI worked in collaboration with Tekmira scientists to develop small interfering

ACGT DNA Technologies is reported to have extensive ties to China’s medical industry, including high-level government officials and private industry contacts The company will focus on the creation

Unlike existing assays, Beacon said that it has created this assay using a synthetic receptor for this compound that replaces traditional enzyme and antibody based approaches. Many additional